RT Journal Article
SR Electronic
T1 Semantic and geographical analysis of Covid-19 trials reveals a fragmented clinical research landscape likely to impair informativeness
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.14.20101758
DO 10.1101/2020.05.14.20101758
A1 Tini, Giulia
A1 Duso, Bruno Achutti
A1 Bellerba, Federica
A1 Corso, Federica
A1 Gandini, Sara
A1 Minucci, Saverio
A1 Pelicci, Piergiuseppe
A1 Mazzarella, Luca
YR 2020
UL http://medrxiv.org/content/early/2020/05/19/2020.05.14.20101758.abstract
AB Background The unprecedented impact of the Covid-19 pandemics on modern society has ignited a “gold rush” for effective treatment and diagnostic strategies, with a significant diversion of economical, scientific and human resources towards dedicated clinical research. We aimed to describe trends in this rapidly changing landscape to inform adequate resource allocation.Methods We developed informatic tools (Covid Trial Monitor) to analyze in real time growth rate, geographical distribution and characteristics of Covid-19 related trials. We defined structured semantic ontologies with controlled vocabularies to categorize trial interventions, study endpoints and study designs. Data and analyses are publicly available at https://bioinfo.ieo.it/shiny/app/CovidCTResults We observe a clear prevalence of monocentric trials with highly heterogeneous endpoints and a significant disconnect between geographic distribution and disease prevalence, implying that most countries would need to recruit unrealistic percentages of their total prevalent cases to fulfill enrolment.Conclusions This geographically and methodologically incoherent growth sheds doubts on the actual feasibility of locally reaching target sample sizes and the probability of most of these trials providing reliable and transferable result. We call for the harmonization of clinical trial design criteria for Covid19 and the increased use of larger master protocols incorporating elements of adaptive designs. Covid Trial Monitor identifies critical issues in current Covid19-related clinical research and represents a useful resource for researchers and policymakers to improve the quality and efficiency of related trialsCompeting Interest StatementThe authors have declared no competing interest.Funding Statementno external funding was received for this workAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata are made available at https://bioinfo.ieo.it/shiny/app/CovidCT